Vir Biotechnology stock gained 5.46 percent before SOLSTICE data

Published on 10/07/2026 at 03:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vir Biotechnology will present Week 96 SOLSTICE results on November 8, 2026. Eight analysts support a Moderate Buy consensus, with targets from USD 18.00 to USD 30.00.

VIR, US92764N1028, Illustration mit AI erstellt.

Vir Biotechnology, Inc. (ISIN US92764N1028) gained 5.46 percent to USD 11.78 on Nasdaq on October 5, 2026. The move came as Yahoo Finance reported the company will present expanded Phase 2 SOLSTICE data for chronic hepatitis delta at the AASLD Liver Meeting.

SOLSTICE data arrive November 8

Vir plans to present Week 96 hepatitis delta response data on November 8, 2026, together with a translational study of liver immune-cell remodeling. The presentation concerns elebsiran and tobevibart, an investigational combination designed to address viral entry and hepatitis B surface antigen production.

The event gives the clinical-stage biotechnology company a defined checkpoint after its second-quarter results. Yahoo Finance identifies November 8 as the date for both oral presentations, with the first session scheduled for 2:15 p.m. MT.

Quarterly figures reset the comparison

Vir reported USD 238.9 million in second-quarter 2026 revenue and USD 80.1 million in net income, according to Simply Wall St. The revenue result compared with USD 1.2 million in the second quarter of 2025, while net income improved from a USD 110.9 million loss.

MarketBeat reported adjusted quarterly earnings per share of USD 0.47 against consensus of USD 0.33 on August 5, 2026. That earnings comparison puts the upcoming clinical readout beside a materially different financial base than the prior-year quarter.

Analysts see a wider valuation gap

MarketBeat lists a Moderate Buy consensus from eight analysts, with an average price target of USD 21.57, a low target of USD 18.00 and a high target of USD 30.00. The average target lies 83.1 percent above the October 5 price of USD 11.78.

Finance leadership also changed before the data event. Business Wire reported on October 1, 2026, that Aziz Sawaf would become chief financial officer effective October 5, replacing interim principal financial officer Brent Sabatini.

VIR stays near its yearly high

Vir Biotechnology was last at USD 11.78 on Nasdaq on October 5, 2026, with a 52-week range of USD 4.82 to USD 11.94. Its market capitalization was USD 2.0 billion as of October 6, 2026, keeping the November clinical presentation central to the stock's valuation debate.